Skip to main content

Table 1 Patient medical history

From: Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report

Treatment line

Start and stop, year/month

Sites of metastasis

Therapeutic schedule

Best response

TTP (months)

1st

1996/ to 1997/3

Lung

Paclitaxel 80 mg/m2 weekly (day 1–8–15, w4)

PR

12

2nd

1997/4 to 2000/1

Lung

Megestrol 160 mg dailya

PR

33

3rd

2000/1 to 2001/1

Lung

Exemestane 25 mg daily

SD

12

4th

2001/2 to 2001/6

Lung

Epirubicin (75 mg/mq day1) and Docetaxel (80 mg/mq day1) w3a

SD

4

5th

2001/7 to 2002/1

Lung

Letrozole (2.5 mg daily) and LHRHa

PD

6

6th

2002/2 to 2002/12

Lung

Vinorelbine 25 mg/m2 IV day 1–>5 w3

PD

10

7th

2002/12 to 2007/10

Lung

Megestrol 160 mg dailyb

PR

58

8th

2007/10 to 2008/5

Lung

Tamoxifen 20 mg daily

PR

7

 

2008/6 to 2009/1

 

No therapy

  

9th

2009/1 to 2011/2

Lung

Capecitabine 1000 mg/mq b.i.d. from days 1 to 14, w3

SD

25

10th

2011/2 to 2013/3

Lung

Cyclophosphamide 50 mg/die PO and Methotrexate 2, 5 mg PO twice a week

SD

25

 

2013/4

Lung, bone

Palliative radiant treatment for bone metastases of sacral spine.

  

11th

2013/5 to 2013/10

Lung, bone, nodes

Carboplatinum (AUC5) w3, Zoledronic acid

PD

5

12th

2013/10 to 2014/4

Lung, bone, nodes, subcutaneous

Eribuline 1.2 mg/m2 day 1–8 w3c Zoledronic Acid

PD

6

13th

2014/5 to 2014/9

Lung, bone, nodes, subcutaneous

Everolimus 10 (5) mg daily and Exemestane 25 mg dailyd

PR

4

  1. TTP time to progression, PR partial response, SD stationarity of disease, PD progression of disease, LHRHa Luteinizing hormone releasing hormone (LHRH) agonist
  2. aPoor tolerance
  3. bRechallenge
  4. cPulmunary thromboembolism
  5. dDeterioration of clinical condition